Status:
COMPLETED
Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
Lead Sponsor:
Ain Shams University
Conditions:
Malignant Pleural Mesothelioma
Eligibility:
All Genders
18+ years
Brief Summary
To Study the Effect of Polymorphisms in Fas Ligand Gene Promoter Region (rs 763110) and Fas gene (rs1800682) on Platinum-Based regimens used in treatment of malignant pleural mesothelioma (MPM)
Detailed Description
This study tries to find a correlation between single nucleotide polymorphisms (SNP) found in promoter region of Fas Ligand gene (rs 763110) and Fas (rs1800682) and clinical outcome on patients with M...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed Malignant Pleural Mesothelioma
- Age of 18 years or more.
- first-line chemotherapy with platinum-Based agents
Exclusion
- history of prior malignancy.
- pregnancy or lactation or any other reason preventing him from taking platinum-Based chemotherapy (AST more than 2.5\* Upper Limit of Normal or Serum bilirubin more than 1.5\* Upper Limit of Normal)
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT02269878
Start Date
April 1 2014
End Date
December 1 2016
Last Update
January 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Abbasia, Egypt